Sun Pharma agrees to supply at MFN pricing to U.S. medicaid programmes
Sun Pharmaceutical Industries Ltd. agreed to provide Most Favoured Nation pricing to U.S. state Medicaid programs. This pricing strategy is part of its long-term growth plan, as the U.S. market accounts for approximately 27% of the company's global revenue. The commitment also includes MFN pricing for future innovative medicines.